Navigation Links
PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
Date:8/25/2008

NDA

-- Analysis of drug review times, performance trends, and success rates by therapeutic category, as well as standard versus priority classification

-- The impact of accelerated approval, orphan drug status, and related programs on review times and outcomes

-- Data regarding other key new drug submissions, including NDA resubmissions, efficacy supplements, and manufacturing supplements

PAREXEL's newly-released The US Drug Approval Trends and Yearbook 2008/2009 is the largest compendium of drug approval trends and metrics ever compiled. To order the compendium ($295 USD), visit http://www.barnettinternational.com/EducationalServices/ or email customerservice@barnettinternational.com. For more PAREXEL book titles published and distributed by Barnett International, a division of Cambridge Healthtech Institute (CHI), visit Barnett Educational Services at http://www.barnettinternational.com/.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 count
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 Guggenheim ... Guggenheim Partners, today announced the hiring of veteran equity ... senior equity analyst. Mr. Butler will focus on the ... our team a wealth of experience and a broad ... Ferrarie , Senior Managing Director and Head of Equities ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... Supply Report, “Consolidation continues to reshape the look and ... in nutrition. Consumer demand for higher-quality ingredients will push ... the North American market have experienced strong market growth ... and ethical attributes in their food and cosmetics to ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... 24, 2011 Champions Biotechnology, Inc. (OTC: CSBR) ... collaboration agreement with Cephalon, Inc. in which Champions ... proprietary chemical compounds, CEP-32496, an inhibitor of mutant ... provided by Cephalon to determine the activity or ...
... ValGenesis, Inc., an industry-leading provider of Validation ... availability of its industry-proven solution as an On-Demand ... MUSA,s Validated Cloud. ValGenesis On-Demand provides ... via the Internet through MUSA,s Validated Cloud on ...
... Medicine, Inc. (RBM), a leading provider of innovative biomarker ... ® , a powerful tool developed at the direction ... Through quantitative measurement of 101 cancer-related proteins, OncologyMAP ... biological pathways that could hold the key to understanding ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development 2
(Date:8/27/2014)... that exists as five strains, none of which have ... the Sudan ebolavirus (SUDV). Although not the strain currently ... as recently as 2012. In a new study appearing ... now report a possible therapy that could someday help ... Sidhu, Jonathan Lai and colleagues explain that about 50-90 ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
(Date:8/27/2014)... each year in U.S. waters and become what are ... crabs, and other species such as turtles. These traps ... who depend on the resources--losses that are largely preventable, ... report, published in the Marine Pollution Bulletin , ... derelict fish trap problem, and so-called "ghost fishing," nationally, ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2New study throws into question long-held belief about depression 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... as current directions and water temperature play a huge ... as they move from rivers and hit ocean waters ... findings inform restoration policies and practices focused on boosting ... findings, from ecologists at the Department of Energy,s Pacific ...
... The National Science Foundation (NSF), in cooperation with ... round of awards under a program that supports ... predictability, resiliency and sustainability of the natural and ... governance of the Arctic. Six projects ...
... international team of researchers says in a new paper ... realm more practical applications for dealing with the ... already exists as does much of the organizational structure, ... ranging from declining snowpack, to severe storms, to sea ...
Cached Biology News:Tracking young salmon's first moves in the ocean 2Tracking young salmon's first moves in the ocean 3Tracking young salmon's first moves in the ocean 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers advocate for climate adaptation science 2Researchers advocate for climate adaptation science 3
Yersinia pestis...
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: